By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
The panel is divided on UiPath's (PATH) future, with concerns about its reliance on license revenue and potential commoditization of its platform, but also opportunities in AI-driven automation and enterprise adoption.
Risk: Commoditization of PATH's platform and erosion of pricing power
Opportunity: Acceleration of enterprise AI adoption and durable ARR growth
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
UiPath, Inc. (NYSE:PATH) has fallen more than 28.5% on a year-to-date basis, and the stock’s short float has exceeded 30%, making it one of the AI Bubble Stocks to Short Now According to Reddit. Wall Street has turned cautious, with 74% of the 23 analysts covering the stock maintaining a Hold rating on the shares.
Recently, on June 1, BMO Capital lowered the price target on UiPath, Inc. (NYSE:PATH) from $14 to $13, while maintaining a Hold rating on the shares. Earlier on May 29, William Blair analyst Patrick McIlwee also maintained a Neutral stance on the stock without disclosing any price targets.
BMO acknowledged that the company posted a solid start to fiscal 2027, with revenue coming in ahead of expectations. However, the firm noted that net new ARR came in modestly below consensus on a constant currency basis, which tempered enthusiasm. Looking ahead, BMO believes larger AI-driven deals and strength among enterprise customers will be the key drivers of net new ARR growth.
Patrick McIlwee of William Blair also acknowledged the first quarter results to be solid, but finds limited upside at current valuation levels. He noted that the company topped revenue expectations, driven by AI-driven agentic and orchestration products’ notable strength. However, he highlighted that much of the revenue beat was driven by license revenue, which likely explains the post-earnings share price pullback despite the headline beat. He noted that although management has guided towards solid growth, the stock trades at a high multiple of forward free cash flow.
UiPath, Inc. (NYSE:PATH) is a firm that works in the development and provision of a software platform to automate business processes.
While we acknowledge the potential of PATH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 9 Most Undervalued Foreign Stocks to Buy Now and 10 Most Undervalued US Stocks According to Hedge Funds.** **
Disclosure: None. Follow Insider Monkey on Google News.
Four leading AI models discuss this article
"The stock's valuation is currently being compressed by a shift in revenue quality, but the extreme short interest makes it a dangerous candidate for a short position at these depressed levels."
The market's reaction to UiPath (PATH) is a classic 'quality of earnings' correction. While revenue beats are headline-friendly, the reliance on license revenue—which is lumpy and non-recurring—over subscription-based ARR growth is a red flag for a SaaS valuation. At current levels, the market is punishing the lack of operating leverage despite the AI narrative. However, the 30% short float suggests a massive 'crowded trade' risk; any positive surprise in enterprise adoption or a shift toward consumption-based pricing models could trigger a violent short squeeze. Investors are currently pricing in a terminal decline in growth rather than a transition period, creating a potential mispricing if the AI agentic roadmap gains traction.
The bear case ignores the stickiness of UiPath’s automation platform; once integrated into enterprise workflows, the switching costs are high enough to protect margins even if growth decelerates.
"The article conflates 'high multiples' with overvaluation without disclosing PATH's actual forward P/E, FCF yield, or growth rate—making it impossible to assess whether the 28% drawdown represents capitulation or justified repricing."
PATH's 28.5% YTD decline and 74% Hold ratings mask a real tension: revenue beat driven by AI products is legitimate, but the market is punishing license revenue mix shift and high forward FCF multiples. The 30%+ short float suggests crowded bearish positioning. BMO's $14→$13 downgrade is marginal; neither analyst disclosed concrete valuation concerns beyond 'high multiples.' The article itself is promotional drivel (see the buried link to 'better AI stocks'), so take its framing with skepticism. Real question: is the license revenue composition a one-time beat or sustainable? If enterprise AI adoption accelerates Q2-Q3, current valuation could re-rate sharply upward.
If license revenue was a pull-forward from deals that should have landed in H2, PATH could face guidance misses ahead—and with 30% short float already positioned, any miss triggers capitulation selling, not bounce-back.
"Elevated short interest plus AI-driven product momentum creates asymmetric upside that Hold ratings and the short thesis overlook."
The article frames PATH as a cautionary AI name with 28.5% YTD drop, >30% short float, and mostly Hold ratings after BMO cut its target to $13. Yet Q1 revenue beat was driven by AI agentic and orchestration strength, and management guided solid growth. The license-heavy nature of the beat may reflect front-loaded enterprise commitments rather than weakness. High short interest introduces squeeze risk if net new ARR reaccelerates in coming quarters via larger AI deals, a dynamic analysts appear to discount at current forward FCF multiples.
License revenue concentration could prove transitory, and if AI deal cycles lengthen or macro spending slows, the already high valuation leaves little room before further multiple compression.
"UiPath's long-run monetization through expanding ARR and AI-enabled automation could justify a multiple re-rating even after this year's pullback."
UiPath's 28% YTD drop, high short interest and a crowd of Hold ratings frames a 'buy the dip' setup that hinges on durable ARR growth from AI-enabled automation. The article notes solid start to fiscal 2027 and stronger AI-driven demand, but flags a modest net-new ARR growth and a rich forward FCF multiple as headwinds. The key test is whether enterprise budgets for automation accelerate enough to turn license and subscription revenue into stable, expanding ARR and improving margins. If Q2 shows better net-new ARR, and gross margin trends improve, the stock could re-rate even as macro AI sentiment cools. Downside remains if deal momentum stalls or macro demand falters.
The AI bull case could be overdone; a few large AI-driven deals are not guaranteed to close, and post-pandemic demand for automation could cool, leaving PATH with high valuations and limited upside if ARR growth stalls or margin leverage is slower than expected.
"UiPath faces long-term margin compression risk if its platform becomes a commoditized orchestration layer for LLMs."
Claude, you’re right to flag the license revenue as a potential pull-forward, but you’re ignoring the structural shift in enterprise procurement. Large-scale AI agentic deployments aren't just 'lumpy'—they are multi-year capital commitments that often bypass standard SaaS ARR reporting in favor of upfront license recognition. The real risk isn't just a guidance miss; it’s that PATH’s platform is becoming a commodity layer for LLMs. If the moat is just orchestration, margins will compress regardless of ARR.
"PATH's squeeze risk is real, but the commodity-layer thesis needs stress-testing against renewal ASP trends, not just Q2 ARR beats."
Gemini's 'commodity layer' risk is underexplored but overstated. PATH's value isn't orchestration alone—it's domain expertise in enterprise process automation, which LLMs can't replicate. However, Gemini nails the real threat: if customers view PATH as interchangeable infrastructure rather than strategic platform, pricing power erodes fast. The squeeze narrative everyone's anchoring on masks this deeper moat question. License revenue timing matters less than whether enterprises renew at current ASPs.
"LLM encroachment risks eroding PATH's renewal pricing power faster than ARR signals reveal."
Claude, your defense of PATH's domain expertise as a durable moat overlooks how quickly LLM fine-tuning on enterprise workflows could commoditize that layer. If orchestration becomes interchangeable, renewal ASPs face compression well before ARR metrics flag it. This undercuts the short-squeeze thesis by making any reacceleration temporary rather than structural, especially with license-heavy beats already pricing in premium positioning.
"Front-loaded license revenue can hide a decelerating ARR renewal cycle, making any reacceleration non-durable and risking margin compression in a downturn."
To Grok: the squeeze thesis presumes reacceleration lasts; the bigger risk is front-loaded license revenue masking a decelerating ARR renewal cycle. If enterprise budgets slow, net-new ARR could disappoint even with AI-driven wins, triggering multiple compression. Even with potential orchestration commoditization, PATH’s data governance and cross-LLM integration create real switching costs; moat isn’t zero, but margins hinge on durable ARR growth—something not guaranteed in a downturn.
The panel is divided on UiPath's (PATH) future, with concerns about its reliance on license revenue and potential commoditization of its platform, but also opportunities in AI-driven automation and enterprise adoption.
Acceleration of enterprise AI adoption and durable ARR growth
Commoditization of PATH's platform and erosion of pricing power